The antibody-drug conjugates (ADCs) are one the fastest growing biotherapeutics in
oncology and are still in their infancy in gastrointestinal (GI) cancer for clinical applications to …

The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in
recent years have fuelled the ongoing development of this class of drugs. These novel …

Gastric cancer (GC) is a prevalent malignant tumor of the digestive system worldwide,
ranking among the top five in terms of incidence and mortality. However, the clinical efficacy …

Abstract Antibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an
antibody to enhance their targeted delivery to tumors, represent a significant advancement …

Simple Summary Since the first antibody–drug conjugate (ADC) was approved in 2000, the
landscape of these targeted drugs has evolved over the years, profoundly changing the …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

In recent years, remarkable breakthroughs have been reported on antibody‐drug
conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade …

Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant
promise for patients with cancer, particularly where existing treatments are limited …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

The clinical development and then the progressive entry in clinical practice of antibody–drug
conjugates (ADC) have marked a transformative advancement in the overall cancer …